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BACKGROUND: The National Epirubicin Adjuvant Trial (NEAT) and BR9601 trials tested the benefit of epirubicin when added to
cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF) compared with standard CMF in adjuvant chemotherapy for women
with early breast cancer. This report details longer follow-up with interesting additional time-dependent analyses.
METHODS: National Epirubicin Adjuvant Trial used epirubicin (E) 3-weekly for four cycles followed by classical (c) CMF for four cycles
(E-CMF) compared with cCMF for six cycles. BR9601 used E 3-weekly for four cycles followed by CMF 3-weekly for four cycles,
compared with CMF 3-weekly for eight cycles.
RESULTS: In all, 2391 eligible patients were randomised and with a median 7.4-year follow-up, E-CMF confirmed a significant benefit
over CMF in both relapse-free survival (RFS) (78% vs 71% 5 years RFS, respectively, hazard ratio (HR)¼ 0.75 (95% CI: 0.65–0.86),
Po0.0001) and overall survival (OS) (84% vs 78% 5 years OS, respectively, HR¼ 0.76 (95% CI: 0.65–0.89), P¼ 0.0007). Interaction
of treatment effect and prognostic factors was demonstrated for duplication of chromosome 17 centromeric enumeration
(Ch17CEP) as previously reported. Poor prognostic factors at diagnosis (ER and PR negative and HER2 positive) showed time-
dependent annual hazard rates for RFS and OS. In univariate analysis, these factors demonstrated more favourable HRs for RFS after
5 years. Treatment effects also suggested a differential benefit for E-CMF within the first 5 years for poor prognosis tumours.
CONCLUSION: Longer follow-up has confirmed E-CMF as significantly superior to CMF for all patients. Ch17CEP duplication was the
only biomarker that demonstrated significant treatment interaction. Standard poor prognostic factors at diagnosis were time-
dependent, and after 5 years disease-free, poor prognosis patients demonstrated favourable HRs for survival.
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The National Epirubicin Adjuvant Trial (NEAT) and BR9601 trials
were designed during 1994–1995 to assess the added value of
anthracyclines in the adjuvant treatment of early breast cancer.
In the early 1990s, cyclophosphamide, methotrexate and
5-fluoruracil (CMF) was the standard treatment regimen in the
United Kingdom. The Early Breast Cancer Trialists Collaborative
Group (EBCTCG) report for 1992 did not assess anthracyclines in
the treatment of early breast cancer (Early Breast Cancer
Trialists’ Collaborative Group, 1992). However, there was some
evidence for anthracycline activity in metastatic disease
(Habeshaw et al, 1991).
In 1994, the importance of scheduling the administration of
anthracyclines became evident. Bonadonna’s studies (Buzzoni et al,
1991; Bonadonna et al, 2004) showed that a block-sequential
delivery of four cycles of doxorubicin, 75 mg m–2, followed by eight
cycles of CMF, was better than a 2 : 1 alternating regimen of the
same drugs (Bonadonna et al, 1995). An additional trial which used
four cycles of doxorubicin after eight cycles of CMF showed no
improvement over a standard 12 cycles of CMF (Moliterni et al,
1991). These findings were consistent with the Norton/Day
mathematical models that predicted better outcomes with block-
sequential therapy (Norton and Day, 1991), than with the alternating
non-cross-resistant regimens suggested by Goldie et al (1982).
The NEAT and BR9601 trials adopted this block-sequential
approach for the anthracycline groups. However, epirubicin was
used instead of doxorubicin to reduce toxicity (Earl and Iddawela,
2004). National Epirubicin Adjuvant Trial administered cCMF,
because of its superior efficacy in metastatic breast cancer
(Engelsman et al, 1991) and because of the importance of dose
delivery of CMF in early breast cancer (Bonadonna and Valagussa,
1981). In the BR9601 trial, CMF was given every 3 weeks to
minimise the need for patients to travel long distances to
specialised centres in Scotland. In addition, we reduced the
sequentially administered CMF to four cycles in the anthracycline
groups of both trials. The control treatments in each trial were of
equal duration, with six cycles of cCMF in NEAT and eight cycles
of 3-weekly CMF in BR9601.
The NEAT and BR9601 randomised phase III trials were designed
jointly and a combined enrolment of 2000 patients was required to
have a statistical power of 85% to detect an absolute difference of 7%
in both overall survival (OS) and relapse-free survival (RFS) between
treatments, with a 5% (two-sided) level of significance. A 48-month
median follow-up analysis of the 2391 eligible patients recruited
showed that E-CMF had significant superiority over CMF in terms of
OS (hazard ratio (HR) 0.67 (95% CI: 0.55–0.82)) and RFS (HR: 0.69
(95% CI: 0.58–0.82)) (Poole et al, 2006).
The primary end points of NEAT and BR9601 were 5-year RFS
and OS. Now with 95% of alive patients having 45 years follow-
up, this manuscript presents the updated joint-trial, primary end
point analysis with 7.4 years median follow-up. This longer follow-
up has also allowed for important analyses of the effect of both
prognostic markers and treatment effects, through time. In
addition, central pathological review of 84% of primary tumours
(histotype and grade), hormone receptors, HER2, TOP2A and
other analyses have been carried out.
MATERIALS AND METHODS
Both trials were approved by the Multi-Centre Research Ethics
Committee and Local Research Ethics Committees at participating
hospitals, and a retrospective tissue block collection was subse-
quently approved in a separate application. Trial co-ordination was
supported by a Cancer Research UK (previously Cancer Research
Campaign) project grant. An educational grant and discounted
epirubicin was provided by Pharmacia, now Pfizer (UK). Pharmacia
did not participate otherwise in the design, data accrual and analysis
or manuscript preparation in these trials.
Patients and treatments
The study design, eligibility criteria, stratification variables and
treatment schedules have been described elsewhere in detail (Poole
et al, 2006). Eligibility included women with completely excised
early breast cancer who required adjuvant chemotherapy, provided
written informed consent, and could start treatment within 10
weeks of surgery. Eligibility also required adequate renal, hepatic
and bone marrow function, no previous exposure to chemotherapy
or radiotherapy, and no prior or concomitant malignancy. Patients
were randomly assigned, by telephone to central locations and by
use of a permuted block, 1 : 1 randomisation, to receive either
E-CMF or CMF. Both trials stratified patients according to treating
centre, age and nodal status. National Epirubicin Adjuvant Trial
additionally stratified according to planned radiotherapy schedule.
Treatment regimens in NEAT were four cycles of epirubicin
(3-weekly) followed by four cycles of CMF (4-weekly) vs six cycles
of CMF (4-weekly) (see Figure 1). BR9601 randomised between
four cycles of epirubicin (3-weekly), followed by four cycles of
CMF (3-weekly) or eight cycles of CMF (3-weekly).
Pathology, immunohistochemistry and fluorescent in situ
hybridisation
Routine pathology tissue blocks from surgery were retrieved and
were reviewed centrally in Cambridge (Elena Provenzano) for
NEAT cases, and in Edinburgh for BR9601 cases, for breast cancer
morphology and tumour grade. Tissue microarrays (TMAs) were
constructed with a single 0.6 mm core from a representative part of
the tumour (172 sample arrayed in each TMA block) and sections
stained for ER, PR, EGFR, HER2, HER3 and Ki67 by immunohis-
tochemistry (IHC), and fluorescent in situ hybridisation (FISH) for
HER2 and TOPO 2A gene copy number and chromosome 17
centromeric enumeration (Ch17CEP copy number) (Bartlett et al,
2010). Tumour blocks were available for 83% of eligible NEAT
patients (1686/2021) and 85% of BR9601 patients (316/370).
Statistical analysis
Primary outcome measures in both trials were RFS and OS.
Relapse-free survival was calculated from the date of surgery to the
date of first relapse; to date of death in women dying without
relapse; or to date of censoring in women alive and relapse-free.
Overall survival was calculated from date of surgery to date of
death, or date of censoring if alive. Survival curves were
constructed using Kaplan–Meier methodology (Kaplan and
Meier, 1958). Log-rank tests assessed differences in outcome by
patient and tumour characteristics, and treatment. Cox-propor-
tional hazards modelling (Cox, 1972) investigated and adjusted for
baseline prognostic factors. Hazard ratios of treatment effects on
the risk of relapse and death were calculated for prognostic
subgroups univariately and displayed as HR plots (Early Breast
Cancer Trialists’ Collaborative Group, 1990). Secondary outcomes
of toxicity, dose intensity and quality of life have been reported
elsewhere (Earl et al, 2008).
All analyses were undertaken using SAS version 9.2 statistical
software (SAS Institute Inc., Cary, NC, USA) and all reported P-
values are two-sided. Protocol violators were analysed within their
randomised groups thus allowing analysis to be undertaken on an
intention-to-treat basis.
RESULTS
Patients
National Epirubicin Adjuvant Trial recruited 2021 eligible patients
April 1996 to July 2001, and BR9601 recruited 370 eligible patients
October 1996 to April 2001. In all, 1189 patients were randomised
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to E-CMF and 1202 patients to CMF (see Figure 1). Patient
characteristics, type and timing of surgery and tumour character-
istics were balanced across treatments (Table 1). In the NEAT
patients, cCMF (po) was used in 64% of patients, IV CMF in 31%
and a combination in 5% (due to toxicity) (Rea et al, 2004).
Cyclophosphamide, methotrexate and fluorouracil delivery type
was balanced between the two treatment arms. A total of 2002
patients’ tumour material was centrally reviewed (84%). Where
pathology data (histotype/grade) and ER/PR/HER2 status were
available from the central reviews, these values were used for the
analysis. If tumour blocks were not made available the previously
recorded local assessments were used.
Overall survival and RFS
With a median follow-up of 7.4 years, 626 deaths (26% of the 2391
eligible patients) have been reported (23% E-CMF, 29% CMF)
(Supplementary Table 1). Median time to death was 3.3 years (range
45 days to 10.1 years), the main cause being breast cancer (91%). Loco-
regional or distant relapse has been reported in 703 (29%) patients
(26% E-CMF, 33% CMF), with distant metastases sites predominantly
reported in the bone, liver and/or lung (79% of sites reported). There
are 773 events (32% of the 2391 patients) in the analysis of RFS (29%
E-CMF, 36% CMF). Follow-up in patients who are alive was equivalent
across trials and treatments.
The E-CMF patients survived significantly longer than CMF
patients, with an unadjusted HR in the E-CMF group of 0.76 (95%
CI: 0.65–0.89, P¼ 0.0007), corresponding to an absolute survival
benefit of 6% (84% vs 78%) at 5 years (Figure 2A). The E-CMF
patients also had significantly longer RFS, with an unadjusted HR
in the E-CMF group of 0.75 (95% CI: 0.65–0.86, Po0.0001), which
corresponds to an absolute RFS benefit of 7% (78% vs 71%) at
5-years (Figure 2B). These findings are unlikely to be due to
an artefact of the slight difference between the duration of
treatment in the E-CMF (28 weeks) and CMF (24 weeks) groups of
the NEAT trial.
Consort Diagram: trial profile for NEAT and BR9601
NEAT
2027 patients randomised
BR9601
374 patients randomised
CMF (191 patients)
8 cycles of 3-weekly CMF 
Cyclophosphamide (750 mg m–2)
Methotrexate (50 mg m–2)
F luorouracil (600 mg m–2)
E-CMF (183 patients)
4 cycles of 3-weekly Epirubicin (100 mg m–2)
followed by 4 cycles of 3-weekly CMF (as above)
E-CMF (1011 patients)
4 cycles of 3-weekly Epirubicin (100 mg m–2)
followed by 4 cycles of 4-weekly CMF (as above)
CMF (1016 patients)
6 cycles of 4-weekly CMF
Cyclophosphamide (100 mg m–2 p.o. on days 1 to 14
or 600 mg m–2 i.v. on days 1 and 8) 
Methotrexate (40 mg m–2)
Fluorouracil (600 mg m–2)
Combined total
2401 patients randomised
CMF  (n = 1207) E-CMF  (n = 1194)
Analysed (n = 1189)
Excluded from analysis; ineligible (n = 5)
Previous malignancies or existing 
metastases discovered post randomisation
Analysed (n = 1202)
Excluded from analysis; ineligible (n = 5)
Previous malignancies or existing 
metastases discovered post randomisation
94% patients with > 5 years FU
Median FU = 7.4 years (IQR 6.4 – 8.7 years) 
348 (29%) deaths, 431 (36%) RFS events
95% patients with > 5 years FU
Median FU = 7.4 years (IQR 6.5 – 8.7 years)
278 (23%) deaths, 342 (29%) RFS events
Received randomised treatment (n = 1182)
7 protocol violations
6 Patients received treatment in the other group
1 Patient declined treatment after cycle 5
Received randomised treatment (n = 1194)
8 protocol violations
2 Patients chose to discontinue treatment
3 Administration errors
3 Patients withdrew consent
both i.v. on days 1 and 8
p.o. = per oral; i.v. = intra-venous; FU = follow-up; RFS = relapse-free survival.
CMF (NEAT): 64% poCMF; 31% ivCMF; 5% both (balanced across treatment arms)
All i.v. on day 1
Figure 1 Consort Diagram.
NEAT and BR9601 adjuvant breast cancer trials of sequential E-CMF
HM Earl et al
1259
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(8), 1257 – 1267
C
li
n
ic
a
l
S
tu
d
ie
s
Prognostic factors
A base Cox model was created of the known prognostic factors of
age (p50 years old: 450 years old), the categorical variable nodal
status (negative: 1–3 positive: 4þ positive), oestrogen receptor
(ER) status (positive: negative), progesterone receptor (PgR) status
(positive: negative), tumour size (p2 cm: 42 cm), tumour grade
(1 and 2 : 3), type of surgery (mastectomy: breast conserving
surgery (BCS) ) along with the laboratory measures available
(Supplementary Table 2). In this model of the 1525 patients with
complete data, treatment (E-CMF:CMF) remained an independent
indicator of residual risk for both OS (HR: 0.70 (95% CI: 0.58–0.86),
P¼ 0.0004) and RFS (HR: 0.72 (95% CI: 0.60–0.86), P¼ 0.0003).
Treatment interaction with prognostic factors:
improvements in OS and RFS
Women in all prognostic groups benefitted from E-CMF when
compared with CMF for both OS and RFS (Figures 3 and 4A and
B). For all but one subgroup there were no statistically significant
interactions between the subgroup and the treatment effect.
CH17CEP duplication was the one biomarker that showed
significant interaction with treatment effect for both OS and
RFS benefit from E-CMF relative to CMF (P-values for hetero-
geneity; P¼ 0.02 and P¼ 0.005, respectively). For all other
variables, no evidence of significant heterogeneity in E-CMF
benefit for OS and RFS, between levels of recorded prognostic
factors were observed, no evidence of any subgroup where
Table 1 Patient characteristics and gene copy number characteristics of
NEAT and BR9601 patients at randomisation
E-CMF,
N (%)
CMF,
N (%)
Age (n¼ 2391)
p50 years old 713 (60) 699 (58)
450 years old 476 (40) 503 (42)
Menopausal status (n¼ 2265)
Pre-menopausal 572 (51) 562 (49)
Peri-menopausal 103 (9) 117 (10)
Post-menopausal 444 (40) 467 (41)
Performance status (n¼ 2090)
0 – Fully active 837 (80) 834 (79)
1 – Restricted 197 (19) 211 (20)
2 – Capable self-care 5 (1) 6 (1)
Type of surgery (n¼ 2381)
Mastectomy 615 (52) 634 (53)
Breast conserving surgery 569 (48) 563 (47)
Surgery randomisation (n¼ 2376)
N 1181 1195
Median (IQR) (days) 26 (20–34) 25 (19–33)
Nodal involvement (n¼ 2391)
0 Nodes involved 336 (28) 337 (28)
1–3 Nodes involved 564 (48) 565 (47)
4þ Nodes involved 289 (24) 300 (25)
Tumour typea (n¼ 2376)
NST/NST with lobular features 1010 (86) 1015 (85)
Classical lobular/pleomorphic lobular 80 (7) 89 (7)
Mixed NST and lobular 27 (2) 24 (2)
Mixed NST and special type 15 (1) 13 (1)
Pure special type 49 (4) 54 (5)
Tumour size (n¼ 2334)
p2 cm 504 (44) 517 (44)
42 and p5 cm 595 (51) 594 (51)
45 cm 60 (5) 64 (5)
VL invasion (n¼ 2391)
Reported 605 (51) 615 (51)
Unreported 584 (49) 587 (49)
Tumour gradea (n¼ 2379)
1 – Well-differentiated 39 (3) 42 (4)
2 – Mod. differentiated 438 (37) 419 (35)
3 – Poorly differentiated 707 (60) 734 (61)
ER statusa (n¼ 2280)
Negative (Allred score 0–2) 465 (41) 474 (41)
Positive (Allred score X3) 669 (59) 672 (59)
PgR status (n¼ 1801)
Negative (Allred score 0–2) 387 (44) 412 (45)
Positive (Allred score X3) 489 (56) 513 (55)
HER2 (n¼ 1907)
Negative 746 (79) 770 (80)
Positive 197 (21) 194 (20)
EGFR (n¼ 1910)
Negative 724 (77) 749 (77)
Positive 218 (23) 219 (23)
HER3 (n¼ 1897)
Negative 669 (72) 684 (71)
Positive 266 (28) 278 (29)
Table 1 (Continued )
E-CMF,
N (%)
CMF,
N (%)
HER1–3 (n¼ 1732)
Negative 378 (44) 375 (43)
Positive 485 (56) 494 (57)
Ki67 (n¼ 1872)
Low (p13%) 360 (39) 376 (40)
High (413%) 571 (61) 565 (60)
Triple negatives (n¼ 1256)
ER neg, PR neg, HER2 neg 190 (30) 195 (31)
ER pos, HER2 neg 433 (70) 438 (69)
HER2 (n¼ 1762)
Normal 690 (78) 705 (80)
Amplification 192 (22) 175 (20)
TOP2A (n¼ 1762)
Normal 792 (90) 801 (91)
Amplification 90 (10) 79 (9)
TOP2A (n¼ 1762)
Normal 789 (89) 782 (89)
Deletion 93 (11) 98 (11)
TOP2A (n¼ 1762)
Normal 699 (79) 703 (80)
Altered (either amplified or deleted) 183 (21) 177 (20)
Ch17CEP (n¼ 1762)
Normal 692 (78) 664 (75)
Duplication 190 (22) 216 (25)
Abbreviations: IQR¼ interquartile range; NEAT¼National Epirubicin Adjuvant Trial;
CMF¼ cyclophosphamide, methotrexate and fluorouracil. Unknowns not shown.
aER and tumour grade and type were analysed centrally in 84%, local values were
used in 16%.
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E-CMF was seen as less effective than CMF, and, in fact, all
subgroups’ CIs of their HRs overlapped the overall OS and RFS
results (Figures 3A and 4B).
Prognostic factors over time with longer follow-up
With 95% of alive patients having 45 years FU, the significance of
known prognostic factors for OS and RFS over three separate time
periods was investigated in a univariate manner; the first 2 years
following definitive surgery, from years 2–5, and from 5 years
onwards (Table 2 for OS and Supplementary Table 3 for RFS).
Similar results were found for OS and RFS, with E-CMF having
lower hazards rates than CMF for the first 5 years, but similar
hazards to CMF after year 5. The following prognostic categories
showed no obvious changes through time; nodal status (1–3,
and 4þ nodes vs negative nodes), surgery (BCS vs mastectomy),
age (o50 years vs X50 years), menopausal status (pre-/peri-
vs post-menopausal), performance status and HER3 IHC (positive
vs normal). Other poor prognostic factors showed an apparent
trend for the HR to reduce with follow-up particularly after 5 years.
These categories include ER negative, PR negative, HER2 positive
and EGFR by IHC, tumour size 42 cm, grade 3 tumours,
HER2 amplification, TOP2A deletion and Ch17CEP duplication.
Therefore, for these poor prognostic factors there is an observed
‘survivor’ bias for patients who remain relapse-free; the poor
prognostic factors defined at the time of diagnosis, show lower
annual HRs for relapse after 5 years, compared with the good
prognosis factors at the time of diagnosis.
Treatment interaction with prognostic factors: annual
hazard rates for OS
The annual hazard rates for OS show an increasing hazard for the
first 3 years after surgery with a subsequent fall to 5 years
(Figure 5). The E-CMF reduces the size of the initial risk rise and
maintains a steady risk thereafter. Analysis of hazard rates over
time by ER status, (Figure 5) showed interesting and distinct
trends that mirrored the prognostic effects through time described
above. ER-positive patients show a steady increase in hazard rates
over the first 5 years for OS. Treatment effect shows that the early
hazard rate peak was abolished by E-CMF when compared with
CMF chemotherapy. However, hazard rates are low in this group.
It is possible that the E-CMF benefit for OS is beginning to emerge
again at 4–5 years. ER-negative patients show the benefit of E-CMF
is greater than in the ER-positive patients, and the hazard rate for
OS becomes the same for CMF and E-CMF at 5 years. Analyses of
annual hazard rates for RFS are included in (Supplementary
Figure 4).
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Figure 2 OS and RFS curves by treatment. (A) OS. (B) RFS.
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Deaths/patients
ECMF CMF
ECMF events
(O-E) Var
*Hazard ratio and CI
(ECMF : CMF)
*Hazard ratio and CI
*Hazard ratio and CI
(ECMF : CMF)
Deaths/patients
ECMF CMF
ECMF events
(O-E) Var
*Hazard ratio and CI
(ECMF : CMF) (ECMF : CMF)
0.0 0.5 1.0 1.5 2.0
ECMF better CMF better
0.0 0.5 1.0 1.5 2.0
ECMF better CMF better
* 95% CI99% CI
AGE
50 years old 151/713 197/699 –30.4 86.8(21.2%) (28.2%) 0.70 (0.53, 0.93)
>50 years old 127/476 151/503 –11.3 69.5(26.7%) (30.0%) 0.85 (0.62, 1.16)
Subtotal 278/1189 348/1202 –41.8 156.3
(23.4%) (29.0%)
0.77 (0.65, 0.90)
(P <0.001)
= 1.4; P =0.24Interaction between two groups 21NODAL STATUS
Negative 45/336 60/337 –8.7 26.2(13.4%) (17.8%) 0.72 (0.43, 1.18)
1–3 nodes involved 118/564 141/565 –12.4 64.7(20.9%) (25.0%) 0.83 (0.60, 1.14)
4+ nodes involved 115/289 147/300 –23.1 65.2(39.8%) (49.0%) 0.70 (0.51, 0.97)
Subtotal 278/1189 348/1202 –44.3 156.2(23.4%) (29.0%) 0.75 (0.64, 0.88)(P <0.001)
= 0.9; P =0.63Heterogeneity between three groups 22
= 0.1; P =0.72Test for trend over three groups 21
TUMOUR SIZE
2cm 80/504 108/517 –14.1 47.0(15.9%) (20.9%) 0.74 (0.51, 1.08)
>2cm 187/655 226/658(34.3%) –27.5 103.0(28.5%) 0.77 (0.59, 0.99)
Subtotal 267/1159 334/1175 –41.6 150.0(23.0%) (28.4%) 0.76 (0.65, 0.89)(P <0.001)
= 0.0; P =0.85Interaction between two groups 21
TUMOUR GRADE
Well/moderate 89/477 102/461 –9.6 47.6(18.7%) (22.1%) 0.82 (0.56, 1.19)
Poor 188/707 245/734 –31.8 108.1(26.6%) (33.4%) 0.75 (0.58, 0.95)
Subtotal 277/1184 347/1195 –41.4 155.8(23.4%) (29.0%) 0.77 (0.66, 0.90)(P <0.001)
= 0.3; P =0.60Interaction between two groups 21
ER STATUS
Negative 123/465 159/474 –23.4 70.3(26.5%) (33.5%) 0.72 (0.53, 0.97)
Positive 142/669 166/672 –12.6 76.9(21.2%) (24.7%) 0.85 (0.63, 1.14)
Subtotal 265/1134 325/1146 –36.1 147.2(23.4%) (28.4%) 0.78 (0.67, 0.92)(P =0.003)
= 1.1; P =0.31Interaction between two groups 21
PgR STATUS
Negative 107/387 152/412 –25.1 64.6
(27.6%) (36.9%)
0.68 (0.49, 0.93)
Positive 105/489 124/513 –7.9 57.2(21.5%) (24.2%) 0.87 (0.62, 1.22)
Subtotal 212/876 276/925 –33.0 121.8(24.2%) (29.8%) 0.76 (0.64, 0.91)(P =0.003)
= 1.9; P =0.17Interaction between two groups 21
Unstratified 278/1189 348/1202 –42.3 156.4(23.4%) (29.0%) 0.76 (0.65, 0.89)(P <0.001)
* 95% CI99% CI
HER2 FISH
Normal 158/690 183/705 –14.8 85.2
(22.9%) (26.0%)
0.84 (0.64, 1.11)
Amplification 66/192 72/175 –9.6 34.1
(34.4%) (41.1%)
0.75 (0.49, 1.17)
Subtotal 224/882 255/880 –24.4 119.3
(25.4%) (29.0%)
0.82 (0.68, 0.98)
(P =0.03)
= 0.3; P =0.59Interaction between two groups 21
TRIPLE NEGATIVE
Triple negative 48/190 61/195 –8.3 27.2
(25.3%) (31.3%)
0.74 (0.45, 1.21)
ER+ HER2– 91/433 106/438 –8.1 49.2
(21.0%) (24.2%)
0.85 (0.59, 1.22)
Subtotal 139/623 167/633 –16.4 76.4
(22.3%) (26.4%)
0.81 (0.65, 1.01)
(P =0.06)
= 0.3; P =0.56Interaction between two groups 21
TOP2A
Normal 171/699 195/703 –15.5 91.4
(24.5%) (27.7%)
0.84 (0.64, 1.11)
Altered 53/183 60/177 –7.2 28.0
(29.0%) (33.9%)
0.77 (0.48, 1.26)
Subtotal 224/882 255/880 –22.7 119.5
(25.4%) (29.0%)
0.83 (0.69, 0.99)
(P =0.04)
= 0.2; P =0.69Interaction between two groups 21
Ch17CEP
Normal 181/692 177/664 –5.3 89.3
(26.2%) (26.7%)
0.94 (0.72, 1.24)
Duplification 43/190 78/216 –16.5 30.2
(22.6%) (36.1%)
0.58 (0.36, 0.93)
Subtotal 224/882 255/880 –21.8 119.5
(25.4%) (29.0%)
0.83 (0.70, 1.00)
(P =0.05)
= 5.3; P =0.02Interaction between two groups 21
Unstratified 278/1189 348/1202 –42.3 156.4
(23.4%) (29.0%)
0.76 (0.65, 0.89)
(P <0.001)
Figure 3 E-CMF improvements in OS. (A) By patient characteristics. (B) By tumour characteristics.
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Events/patients
ECMF CMF
ECMF events
(O-E) Var
*Hazard ratio and CI *Hazard ratio and CI
(ECMF : CMF) (ECMF : CMF)
Events/patients
ECMF CMF
ECMF events
(O-E) Var
*Hazard ratio & CI *Hazard ratio & CI
(ECMF : CMF) (ECMF : CMF)
* 95% CI99% CI
50 years old
AGE
197/713 243/699 –33.2 109.7
(27.6%) (34.8%)
0.74 (0.58, 0.95)
>50 years old 145/476 188/503 –22.0 83.2(30.5%) (37.4%) 0.77 (0.58, 1.02)
Subtotal 342/1189 431/1202 –55.1 192.9(28.8%) (35.9%) 0.75 (0.65, 0.87)(P <0.001)
= 0.1; P =0.79Interaction between two groups 21
NODAL STATUS
Negative 58/336 72/337 –8.7 32.5(17.3%) (21.4%) 0.76 (0.49, 1.20)
1–3 nodes involved 148/564 180/565 –19.2 82.0(26.2%) (31.9%) 0.79 (0.60, 1.05)
4+ nodes involved 136/289 179/300 –30.0 78.4(47.1%) (59.7%) 0.68 (0.51, 0.91)
Subtotal 342/1189 431/1202 –57.9 192.8(28.8%) (35.9%) 0.74 (0.64, 0.85)(P <0.001)
= 0.9; P =0.63Heterogeneity between three groups 22
= 0.6; P=0.46Test for trend over three groups 21
TUMOUR SIZE
2cm 106/504 140/517 –18.2 61.5
(21.0%) (27.1%)
0.74 (0.54, 1.03)
>2cm 225/655 276/658 –36.1 124.9(34.4%) (41.9%) 0.75 (0.59, 0.94)
Subtotal 331/1159 416/1175 –54.3 186.4(28.6%) (35.4%) 0.75 (0.65, 0.86)(P <0.001)
= 0.0; P =0.97Interaction between two groups 21
TUMOUR GRADE
Well/moderate 120/477 141/461 –15.5 65.1(25.2%) (30.6%) 0.79 (0.57, 1.08)
Poor 221/707 287/734 –38.1 126.8(31.3%) (39.1%) 0.74 (0.59, 0.93)
Subtotal 341/1184 428/1195 –53.6 192.0(28.8%) (35.8%) 0.76 (0.66, 0.87)(P <0.001)
= 0.2; P =0.68Interaction between two groups 21
ER STATUS
Negative 142/465 182/474 –27.1 80.7(30.5%) (38.4%) 0.71 (0.54, 0.95)
Positive 184/669 222/672 –21.1 101.4(27.5%) (33.0%) 0.81 (0.63, 1.05)
Subtotal 326/1134 404/1146 –48.2 182.1(28.7%) (35.3%) 0.77 (0.66, 0.89)(P <0.001)
= 0.7; P =0.39Interaction between two groups 21
PgR STATUS
Negative 124/387 169/412 –26.5 73.1(32.0%) (41.0%) 0.70 (0.51, 0.94)
Positive 133/489 166/513 –15.6 74.7(27.2%) (32.4%) 0.81 (0.60, 1.09)
Subtotal 257/876 335/925 –42.1 147.8(29.3%) (36.2%) 0.75 (0.64, 0.88)(P <0.001)
= 0.9; P =0.35Interaction between two groups 21
Unstratified 342/1189 431/1202 –55.9 193.0(28.8%) (35.9%) 0.75 (0.65, 0.86)(P <0.001)
0.0 0.5 1.0 1.5 2.0
ECMF better CMF better
0.0 0.5 1.0 1.5 2.0
ECMF better CMF better
* 95% CI99% CI
HER2 FISH
Normal 189/690 229/705 –24.0  104.4
(27.4%) (32.5%)
0.79 (0.62, 1.02)
Amplification 74/192 78/175 –9.4 37.5
(38.5%) (44.6%)
0.78 (0.51, 1.18)
Subtotal 263/882 307/880 –33.4 141.9
(29.8%) (34.9%)
0.79 (0.67, 0.93)
(P =0.005)
= 0.0; P =0.91Interaction between two groups 21
TRIPLE NEGATIVE
Triple negative 54/190 70/195 –10.6   30.9
(28.4%) (35.9%)
0.71 (0.45, 1.13)
ER+ HER2– 115/433 137/438 –12.5 63.0
(26.6%) (31.3%)
0.82 (0.59, 1.14)
Subtotal 169/623 207/633 –23.0 93.9(27.1%) (32.7%) 0.78 (0.64, 0.96)(P =0.02)
= 0.4; P =0.51Interaction between two groups 21
TOP2A
Normal 205/699 240/703 –23.4 111.1
(29.3%) (34.1%)
0.81 (0.63, 1.03)
Altered 58/183 67/177 –8.1 31.1
(31.7%) (37.9%)
0.77 (0.49, 1.22)
Subtotal 263/882 307/880 –31.6 142.2
(29.8%) (34.9%)
0.80 (0.68, 0.94)
(P =0.008)
= 0.1; P =0.80Interaction between two groups 21
Ch17CEP
Normal 216/692 215/664 –8.9 107.5
(31.2%) (32.4%)
0.92 (0.72, 1.18)
Duplification 47/190 92/216 –22.0 34.7
(24.7%) (42.6%)
0.53 (0.34, 0.82)
Subtotal 263/882 307/880 –30.9 142.2(29.8%) (34.9%) 0.80 (0.68, 0.95)(P =0.01)
= 8.0; P =0.005Interaction between two groups 21
Unstratified 342/1189 431/1202 –55.9 193.0
(28.8%) (35.9%)
0.75 (0.65, 0.86)
(P <0.001)
Figure 4 E-CMF improvements in RFS. (A) By patient characteristics. (B) By tumour characteristics.
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Acute leukaemia
Three cases of acute leukaemia were seen in the E-CMF patients
(Supplementary Table 1), one acute pro-myelocytic, one acute
myeloid and the other acute lymphoblastic leukaemia.
DISCUSSION
Longer follow-up of the NEAT and BR9601 studies confirms the
previously reported significant benefit for E-CMF in terms of both
RFS and OS. This trial is one of the few to demonstrate a
statistically significant benefit from anthracyclines (Coombes et al,
1996; Levine et al, 1998), and is consistent with the meta-analysis
of anthracycline-based therapy trials reported by the EBCTCG
(Early Breast Cancer Trialists’ Collaborative Group, 2005).
Reporting of comprehensive and longer follow-up data remains
as important as ever for these trials, as the results become
increasingly stable and robust. Even in the era of widespread
taxane use, more intensive dose-dense adjuvant regimens, and
targeted therapy with Herceptin in HER2-positive patients, longer
follow-up reporting of older adjuvant breast cancer trials remains
vital in order to confirm the activity of these regimens through
time. In addition, it is increasingly recognised that breast cancer
populations contain a number of important subgroups in which
the effects of adjuvant chemotherapy may be seen many years after
treatment. Reporting of longer follow-up allows for more robust
analysis of known prognostic and predictive factors in the different
groups and also research into new biomarkers.
The trial has significantly contributed data to a comprehensive
translational analysis of HER2 and TOP2A as biomarkers of
response to anthracyclines (Di Leo et al, 2011). The recognition of
Ch17CEP duplication as a powerful predictor of anthracycline
benefit was first reported from translational research in this trial
(Bartlett et al, 2010). In addition, comprehensive analysis of health
economic cost effectiveness of adjuvant chemotherapy in breast
cancer has used data from this trial (Campbell et al, 2011).
It is now well recognised that anthracyclines can cause a dose-
dependent increase in the incidence of acute leukaemia (Praga
et al, 2005). In this report, there was an incidence of acute
leukaemia of 0.25% for an epirubicin dose of 400 mg m–2, which as
anticipated is lower than that reported in the Canadian MA-5 trial
in which the incidence was 1.4% for an epirubicin dose of
720 mg m–2 (Levine et al, 1998). Nevertheless, the effect size for
E-CMF over CMF is similar for our trial reported here, and the
Canadian study. The conclusion is that block-sequential delivery of
anthracycline in E-CMF produces a similar treatment effect to that
seen in the MA-5 trial, but because the cumulative dose of
epirubicin in MA-5 is nearly twice than that it our trial, the rate of
leukaemia is five times more common in the Canadian trial. The
E-CMF is among the most effective and the safest anthracycline-
containing adjuvant regimen for early breast cancer.
The NEAT and SCTBG BR9601 groups have maintained a
translational research programme. A trial tumour bank, with
collection of 84% of the original formalin-fixed paraffin-embedded
tumour blocks has allowed not only for central pathological
review, but also for the creation of TMAs and for IHC and FISH
analysis.
In this longer-term analysis, it has been possible to compare
survival hazard rates by year of follow-up. This has shown a peak
in hazard rates at 1–2 years for relapse, which is followed by a peak
for death at 2–3 years. This is in keeping with previous
epidemiological evidence of an early peak of relapse in the
first 2 years following surgery (Hilsenbeck et al, 1998; Retsky et al,
2008).
Analysis of well-recognised poor prognostic factors through
time showed that for the majority there was a trend for these
factors to lose their prognostic significance. This ‘time-depen-
dency’ of prognostic factors defined at diagnosis was first reported
in 1998 by the University of Texas at San Antonio group, which
analysed 2873 early breast cancer patients with up to 17 years of
RFS follow-up (Hilsenbeck et al, 1998). By way of illustration from
our own data, at 5 years follow-up, a relapse-free patient with an
ER-negative tumour will have a lower ongoing HR for relapse and
death than a patient with an ER-positive cancer. In other words,
for prognostic factors at diagnosis predicting a poor outcome the
relapse-free survivor at 5 years has survived her most ‘at risk’ time.
The ER-positive patients (good prognosis) have a continued albeit
small, risk after 5 years. This has also been demonstrated recently
Table 2 HRs over time for overall survival (OS) by prognostic factors at diagnosis
Univariate HR (95% CI) for OS over time
Factor Grouping 0–2 years 2–5 years 5þ years
Treatment CMF, E-CMF 0.64 (0.46–0.88) 0.69 (0.55–0.87) 1.05 (0.78–1.41)
Age p50 years, 450 years old 1.39 (1.02–1.90) 1.22 (0.97–1.53) 1.11 (0.82–1.50)
Menopausal status Pre/peri, post 1.62 (1.18–2.23) 1.21 (0.96–1.53) 0.96 (0.70–1.32)
Performance status 0, 1/2 1.26 (0.85–1.86) 1.39 (1.05–1.85) 1.07 (0.73–1.57)
Surgery BCS, mastectomy 2.06 (1.47–2.90) 1.29 (1.02–1.62) 1.48 (1.09–2.00)
Nodal status Negative, 1–3 nodes 1.13 (0.72–1.77) 1.38 (1.00–1.92) 1.98 (1.27–3.09)
Negative, 4þ nodes 2.94 (1.91–4.52) 3.34 (2.41–4.63) 3.45 (2.17–5.47)
Tumour size p2 cm, 42 cm 2.21 (1.54–3.17) 1.94 (1.51–2.50) 1.63 (1.20–2.23)
VL invasion Unreported, reported 1.85 (1.33–2.58) 1.61 (1.27–2.03) 1.55 (1.15–2.09)
Tumour grade Well/moderately, poorly differentiated 2.78 (1.86–4.13) 1.98 (1.53–2.56) 0.87 (0.65–1.17)
ER status Positive, negative 3.30 (2.34–4.66) 1.41 (1.11–1.79) 0.69 (0.49–0.96)
PgR status Positive, negative 5.23 (3.43–7.98) 1.47 (1.13–1.91) 0.69 (0.47–1.00)
HER2 Negative, positive 2.44 (1.72–3.46) 1.91 (1.44–2.53) 0.97 (0.62–1.53)
EGFR Negative, positive 2.01 (1.41–2.85) 1.13 (0.83–1.53) 0.86 (0.57–1.30)
HER3 Positive, negative 1.02 (0.70–1.48) 1.19 (0.88–1.60) 0.93 (0.64–1.33)
HER1–3 Negative, positive 2.28 (1.53–3.41) 1.21 (0.93–1.58) 1.03 (0.73–1.47)
Ki67 Low, high 1.16 (0.82–1.65) 1.24 (0.95–1.63) 0.89 (0.63–1.25)
Triple negatives ER positive and HER2 negative, triple negative 3.48 (2.17–5.57) 1.50 (1.07–2.12) 0.46 (0.26–0.81)
HER2 Normal, amplification 2.32 (1.61–3.33) 1.91 (1.44–2.53) 1.13 (0.72–1.77)
TOP2A Amplification, normal 1.82 (0.85–3.91) 1.05 (0.68–1.64) 0.93 (0.52–1.65)
TOP2A Normal, deletion 2.02 (1.30–3.16) 1.76 (1.23–2.51) 0.96 (0.51–1.77)
TOP2A Normal, altered 1.30 (0.86–1.95) 1.39 (1.03–1.87) 1.02 (0.65–1.59)
Ch17CEP Normal, duplication 1.38 (0.94–2.04) 1.25 (0.93–1.68) 0.86 (0.55–1.33)
Abbreviations: BCS¼ breast conserving surgery; CI¼ confidence interval; HR¼ hazard ratio; CMF¼ cyclophosphamide, methotrexate and fluorouracil.
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in another study, which looked at intrinsic IHC categorised
subtypes of breast cancer (Perou et al, 2000) of over 10 000
patients, followed for up to 15 years (Blows et al, 2010).
All women treated within the trial, no matter the prognostic
subgroup of their breast cancer, benefitted from E-CMF when
compared with CMF chemotherapy, and there were no prognostic
subgroups where E-CMF showed a detrimental effect. However, the
only prognostic/predictive factor to significantly interact with the
benefit from anthracyclines was Ch17CEP copy number (Bartlett
et al, 2010).
In conclusion, this updated analysis of NEAT and BR9601 trials
at 7.4 years median follow-up adds to the EBCTCG data in respect
of the advantage of anthracyclines and confirms E-CMF as a highly
effective standard adjuvant therapy for early breast cancer, with a
benefit maintained through time in longer follow-up. Block-
sequential use of a maximum cumulative dose of epirubicin of
400 mg m–2 with CMF is not only effective, but also is associated
with a lower incidence of acute leukaemia than that seen with
other similarly effective anthracycline-containing regimens (Praga
et al, 2005). Increased copy number Ch17CEP demonstrated a
significant interaction with anthracycline treatment effect. Stan-
dard poor prognostic factors defined at diagnosis (ER negative, PR
negative and HER2 positive) demonstrated their prognostic effects
during the first 5 years of follow-up and the differential benefit
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Figure 5 Annual hazard rates and 95% CIs, split by treatment. (A) OS. (B) RFS.
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for E-CMF in these patients may also be concentrated within the
first 5 years. This potential effect should be explored in further
meta-analysis.
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